ERBB2 and breast carcinoma: Previous studies in triple-negative breast cancer have investigated the efficacy and safety of DA [22, 36, 37] and PD-1/PD-L1-inhibitor [30, 38–40]; however, there are no studies on their combined effect in HER2-positive breast cancer.